- 1 Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal
- 2 route among adult who had received CoronaVac
- 4 Authors:

- 5 Rapisa Nantanee, MD<sup>a,b</sup>, Puneyavee Aikphaibul, MD<sup>a,c</sup>, Peera Jaru-Ampornpan, PhD<sup>d</sup>, Pimpayao
- 6 Sodsai, PhD<sup>e</sup>, Orawan Himananto, PhD<sup>f</sup>, Tuangtip Theerawit, RN<sup>a</sup>, Jiratchaya Sophonphan,
- 7 MSc<sup>g</sup>, Punyot Tovichayathamrong, MD<sup>h</sup>, Kasama Manothummetha, MD<sup>h</sup>, Tysdi Laohasereekul,
- 8 MD<sup>h</sup>, Narin Hiransuthikul, MD, PhD<sup>i</sup>, Nattiya Hirankarn, MD, PhD<sup>e</sup>, Thanyawee Puthanakit,
- 9 MD<sup>a</sup> on behalf of the Study Team\*
- <sup>a</sup> Center of Excellence in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University,
- 12 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand
- 13 b Pediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and
- 14 Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King
- 15 Chulalongkorn Memorial Hospital, The Thai Red Cross Society, 1873, Rama IV Rd,
- 16 Pathumwan, Bangkok, 10330, Thailand
- 17 <sup>c</sup> Division of Pediatric Dermatology, Department of Pediatrics, Faculty of Medicine,
- 18 Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross
- 19 Society, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand
- <sup>d</sup> Virology and Cell Technology Research Team, National Center for Genetic Engineering and
- 21 Biotechnology (BIOTEC)

- <sup>e</sup>Center of Excellence in Immunology and Immune-mediated Diseases, Department of
- 23 Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV Rd, Pathumwan,
- 24 Bangkok, 10330, Thailand
- 25 <sup>f</sup> Monoclonal Antibody Production and Application Research Team, National Center for Genetic
- 26 Engineering and Biotechnology (BIOTEC)
- <sup>g</sup> The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red
- 28 Cross AIDS Research Centre, Bangkok, Thailand
- <sup>h</sup> Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV
- 30 Rd, Pathumwan, Bangkok, 10330, Thailand
- 31 Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn
- 32 University, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand
- 34 **Corresponding author:** Thanyawee Puthanakit, MD
- 35 Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics,
- 36 Faculty of Medicine, Chulalongkorn University
- 37 1873, Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.
- 38 Telephone: (+66)2-2564930
- 39 E-mail: thanyawee p@chula.ac.th
- \*Additional study team members are listed.
- 42 **Highlights:**

- Intradermal AZD1222 booster vaccine gave comparable short-term immunogenicity but
- lower 90-day immunogenicity with conventional intramuscular vaccine.

- Lower systemic but higher local reactogenicity was found in intradermal AZD1222
- 46 booster vaccine.

- Blister and pruritus could be seen after intradermal AZD1222 booster vaccine.
- Word counts: 3295, Abstract 300
- 41 References, 2 Tables, 3 Figures, 1 Supplementary Table, 1 Supplementary Figure
- 51 Thai clinical trial registry: TCTR 20210817003

52 **Abstract** 53 **Background** Currently, booster dose is needed after 2 doses of inactivated COVID-19 vaccine. With limited 54 55 resource and shortage of COVID-19 vaccine, intradermal(ID) administration might be a potential 56 dose-sparing strategy. 57 **Objective** 58 To determine antibody response and reactogenicity of ID ChAdOx1 nCoV-19 59 vaccine(AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose 60 CoronaVac(SV) in healthy adult. 61 Methods 62 This is a prospective cohort study of adult aged 18-59 years who received 2-dose SV at 14-35 63 days apart for more than 2 months. Participants received ID AZD1222 at fractional low dose(1x10<sup>10</sup> viral particles,0.1ml). Antibody responses were evaluated by surrogate virus 64 65 neutralization test(sVNT) against wild type and delta variant and anti-spike-receptor-binding-66 domain immunoglobulin G(anti-S-RBD IgG) at prior, day14 or 28, and day90 post booster. 67 Solicited reactogenicity was collected during 7 days post-booster. Primary endpoint was the 68 differences of sVNT against delta strain ≥80% inhibition at day14 and 90 compared with the 69 parallel cohort study of 0.5-ml intramuscular(IM) route. 70 **Results** 71 From August 2021, 100 adults with median (IQR) age of 46(41-52) years participated. At baseline, geometric means(GMs) of sVNT against delta strain prior to booster were 72 73 22.4% inhibition(95% CI 18.7-26.9) and of anti-S-RBD IgG were 109.3(95.4-125.1)BAU/ml. 74 GMs of sVNT against delta strain were 92.9% inhibition (95% CI 87.7-98.3) at day14 and

- 75 73.1%inhibition(66.7-80.2) at day90 post ID booster. The differences of proportion of
- participants with sVNT to delta strain ≥80% inhibition in ID recipients versus IM were
- 77 +4.2%(95%CI-2.0to10.5) at day14, and -37.3%(-54.2to-20.3) at day90. Anti-S-RBD IgG GMs
- 78 were 2037.1(95%CI1770.9-2343.2) at day14 and 744.6(650.1-852.9) BAU/ml at day90,
- 79 respectively. Geometric mean ratios(GMRs) of anti-S-RBD IgG were 0.99(0.83-1.20) at day14,
- and 0.82(0.66-1.02) at day90. Only 18% reported feverish, compared with 37% of IM(p=0.003).
- 81 Only 18% reported feverish, compared with 37% of IM(p=0.003). Common reactogenicity was
- 82 erythema(55%) at injection site while 7% reported blister.
- 83 Conclusion

- Low-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared
- with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity.
- 87 **Keywords**: SARS-CoV2 vaccine, booster dose, AZD1222, Neutralizing antibody titer, anti-
- 88 SARS CoV2 IgG, CoronaVac vaccine, ChAdOx1 nCoV-19 vaccine, intradermal
- 90 **Abbreviations**:
- 91 BAU = Binding-antibody unit
- 92 BMI = Body mass index
- 93 CMI = Cell-mediated immunity
- 94 ELISpot = Enzyme-linked immunospot
- 95 GM = Geometric mean
- 96 GMR = Geometric mean ratio

- 97 ID = Intradermal
- 98 IM = Intramuscular
- 99 PBMC = Peripheral blood mononuclear cell
- 100 SFU = Spot forming unit
- 101 S-RBD = Spike receptor binding domain
- sVNT = Surrogate virus neutralization test

#### 1. Introduction

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

Global report of Coronavirus disease (COVID-19) infection was over 250 million cases with more than 5 million deaths [1], despite over 7 billion doses of vaccination have been administered. In Thailand, as of November 2021, more than 2 million reported COVID-19 infection with over 20,000 deaths. Inactivated COVID-19 vaccine, CoronaVac (Sinovac Life Sciences, Beijing, China), was used for mass vaccination in several countries e.g., Thailand, China, Brazil, and Chile. Effectiveness of CoronaVac for prevention of COVID-19 was 65.9% from study in Chile [2] and 36.8% from study in Brazil [3]. With the rising of delta variant (B.1.617.2) of SAR-CoV-2 globally, the neutralizing activity induced by CoronaVac declined [4] Hence, heterologous prime boost vaccination may provide better immunogenicity. With AZD1222 followed by BNT162b2 heterologous prime boost vaccination, this vaccination strategy provided highest T cell reactivity compared with homologous vaccination [5, 6]. Standard administration of currently available COVID-19 vaccine is via intramuscular injection. Routes for vaccine administration could be intramuscular (IM), intradermal (ID) in which efficacy is related to the immunogenicity [7]. ID administration offers potential dosesparing benefit compared with intramuscular administration, rabies vaccination as example. ID vaccination is a technique in which the vaccine is administered into dermis which is rich in antigen presenting cells such as dermal dendritic cells [8]. Because of the abundance of antigen presenting cells in skin, ID administration required less antigenic dose (usually 20%-30% of standard dose) to induce immune responses than standard IM vaccination. Many studies showed effective immune response by ID vaccination including influenza, rabies, hepatitis B, Bacille Calmette-Guerin (BCG), and polio vaccination [7, 9-12]. For influenza vaccine, a systematic review and meta-analysis showed comparable seroprotection rates for 9-ug ID with 15-ug IM

injection with higher local adverse event particularly erythema and swelling [9]. For rabies vaccine, ID schedules offer advantages through savings in costs, doses and time as recommended by WHO and also approved use on label of vaccine [12].

Fractionated-dose ID COVID-19 vaccine is the potential for rapid achievement of herd immunity based on other vaccines reported [7]. Study of one-tenth dose of mRNA-1273 ID vaccination showed comparable anti-spike IgG and anti-RBD IgG responses to conventional IM vaccination at 2 weeks post primary vaccination series [13]. However, one-fifth dose of BNT162b2 ID booster in healthy Thai adult post 2-dose CoronaVac failed to boost T cell response at 14 days, despite robust neutralizing antibodies response [14]. A case report of ID AZD1222 after 2 doses of CoronaVac showed increase of antibodies and T cell responses against spike protein which neutralizing antibody increased to almost 100% with minimal local reaction at 2-3 weeks after booster [15].

This study aims to evaluate immunogenicity and reactogenicity of ID AZD1222 booster dose in adults who had received 2 doses of CoronaVac.

#### 2. Methods

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

## 2.1 Study design and participants

This study was conducted at Chulalongkorn University Health Center, Faculty of Medicine, Chulalongkorn University, Bangkok Thailand. This is a prospective cohort study. The participants who aged 18 – 59 years old and received two doses of CoronaVac for at least 60 days, 14 – 35 days apart were included in this study. The exclusion criteria were receiving any immunosuppressants or blood products within 3 months before the enrollment or receiving any vaccines within 2 weeks. All participants gave written informed consent prior to study enrollment. This study was registered in Thai Clinical Trials Registry (thaiclinicaltrials org, TCTR 20210817003). Immunogenicity parameters were compared with the parallel randomized controlled trial on healthy adult with standard dose and low dose IM administration of AZD1222 booster after completing 2 doses of CoronaVac (TCTR20210722003), conducted at same settings and lab. We compared the results of this study with conventional standard dose (0.5 ml) IM group. Institutional review board of Faculty of Medicine, Chulalongkorn University approved this study (IRB no. 663/64) and parallel IM AZD1222 booster study (IRB no. 600/64). 2.2 Study procedures One hundred participants were recruited in this study. At baseline, the history of SARS-CoV-2 vaccination and exposure to confirmed case within 3 months were taken. Blood sample was collected prior to giving a booster dose. The participants received ID AZD1222 lot number A1009, manufactured by Siam Bioscience Co., Ltd., 0.1 ml (1 x 10<sup>10</sup> viral particles). The

vaccination was performed by trained physician/nurse (RN and TT). The solicited local and

systemic reactogenicity during 7 days after vaccination was recorded in the diary. The solicited reactogenicity included fever, pain, swelling, erythema, headache, malaise, myalgia, arthralgia, vomiting, and diarrhea. Scheduled visits were day 14 for 50 participants, day 28 for 50 participants. At day 90, 40 participants were scheduled, to collect reactogenicity data and perform blood collection.

The cell-mediated immunity (CMI) sub study was performed among 20 participants, at baseline, day 28, and day 90, with enzyme-linked immunospot (ELISpot) assay to evaluate T and B cell responses.

### 2.3 Immunogenicity outcomes

All participants' samples were tested for spike receptor binding domain (S-RBD) IgG, and functional neutralizing antibody (NAb) against SARS-CoV-2 wild type and delta variants by surrogate virus neutralization test (sVNT). All of the immunogenicity results in ID group were compared with IM participants at equivalent time points.

### Quantitative spike receptor binding domain IgG (anti-S-RBD IgG) ELISA

The ELISA protocol was adapted from Amanat *et al.* (2020) [16]. Briefly, diluted serum samples were incubated in 96-well plates coated with purified recombinant Myc-His-tagged S-RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1). Then, ELISA was performed. Anti-S-RBD IgG level was reported in binding-antibody units (BAU/mL) following conversion of OD450 values with the standard curve using known units of WHO international standard (NIBSC 20/136). We used anti-S-RBD IgG level at 506 BAU/ml, which is correlated with 80% vaccine efficacy reported by the Oxford COVID vaccine trial group [17], as a cut off.

Surrogate virus neutralization test (sVNT)

A surrogate virus neutralization test was set up as previously described in Tan *et al.* (2020) [18]. Recombinant SRBD from the wild-type (Wuhan-Hu-1) and delta (B.1.617.2) strains were used. Serum samples - SRBD mixture were incubated in 96-well plates coated with 0.1 µg/well recombinant human ACE2 ectodomain (GenScript). Then, ELISA was performed. The negative sample was pre-2019 human serum. The % inhibition was calculated as follows:

$$\% inhibition = 100 \times \left[1 - \frac{sample OD 450}{negative OD 450}\right]$$

## Enzyme-linked immunospot (ELISpot) assay to evaluate T and B cell responses

For T cell, ELISpot assay using a Human IFN- $\gamma$  ELISpotPro<sup>TM</sup> kit (Mabtech, Stockholm, Sweden) was used for SARS-CoV-2-specific T cell responses in fresh peripheral blood mononuclear cells (PBMCs). Briefly,  $2.5\Box\times\Box10^5$  PBMCs were stimulated in AIM-V medium with overlapping peptide pool from 100 peptides of SARS-CoV-2 Spike (S) defined peptides and 101 peptides from the nucleoprotein (N), membrane protein (M), open reading frame proteins (O) (Mabtech, Stockholm, Sweden) at a final concentration of 2  $\mu$ g/ml for 20 hours. Negative control and positive control, anti-CD3, were also included. The spots were counted using ImmunoSpot analyzer. Spot counts for negative control wells were subtracted from the test wells to generate normalized readings, these are presented as spot forming unit (SFU) per million PBMCs.

For B cells, Human IgG SARS-CoV-2 RBD ELISpot PLUS (ALP) kit (Mabtech, Stockholm, Sweden) was used for SARS-CoV-2-specific B cell responses. Briefly, the memory B cells were differentiated into antibody secreting cells by pre-stimulating the fresh PBMCs with R848 and IL-2 for 72 hours. Unstimulated well was also used as negative control. Stimulated and

unstimulated PBMCs ( $5 \square \times \square 10^5$  cells per well) were added into ELISpot plate and incubated for 18 hours. An RBD-WASP antigen was added into RBD-specific IgG detected well while MT78/145- biotinylated antibodies were added into total IgG detected well, positive control. Anti-WASP-ALP was added into RBD-specific IgG detected well and negative control well while streptavidin-ALP was added into total IgG detected well. Spot counting was performed in the same method as T cells.

### 2.4 Reactogenicity

Solicited reactogenicity was recorded by participants using diary. All symptoms were graded in 3 grades [19]: grade 0 for no symptom; grade 1 for mild symptom, which was not interfere with activities or vomiting 1-2 times/day or diarrhea 2-3 times/day; grade 2 for moderate symptom, which interfered with activities or need to take medication, or vomiting more than 2 times/day or diarrhea 4-5 times/day; grade 3 for severe symptom, which incapacitated or need hospitalization or diarrhea 6 or more times/day. Fever was graded as grade  $1 (38.0-38.4^{\circ}\text{C})$ , grade  $2 (38.5-38.9^{\circ}\text{C})$ , grade  $3 (39-40^{\circ}\text{C})$ , and grade 4 (more than  $40^{\circ}\text{C}$ ). Unsolicited adverse events were also recorded at all visits by study team.

## 2.5 Statistical analysis

Demographic and clinical characteristics were described for the subjects. Continuous variables were expressed as median (interquartile range: IQR) and number with percentage for categorical variables. Differences in continuous and categorical variables between two groups were assessed using a Wilcoxon rank sum test, Chi-square test, or fisher exact test, respectively. The sVNT results, to either wild type or delta strain, of more than 80% were used to classify the

achievement of 80% protection against symptomatic infection. The anti-S-RBD IgG of more than 506 BAU/ml were used in this study as a cut off for protective antibody level, which previously reported to be associated with 80% vaccine efficacy against primary symptomatic COVID-19 [20].

We presented primary comparisons between ID and IM group in terms of the differences of proportion of participants achieving sVNT ≥80% inhibition. Non-inferiority was concluded if the lower bound of the 95% CI did not exceed -10%. Geometric means (GMs) and geometric mean ratios (GMRs) with 95% confidence interval of anti-S-RBD IgG and sVNT, at day 0, 14, 28, and 90 after booster vaccination, were calculated. Non-inferiority was concluded if the lower bound of the 95% CI did not exceed 0.67 for the GMR of anti-S-RBD. All P-values reported are two-sided. Statistical significance was defined as P<0.05. Stata version 15.1 (Stata Corp., College Station, Texas), was used for analysis.

#### 3. Results

#### 3.1 Baseline characteristic

The participants were enrolled during August 2021. The demographic data was shown in Table 1. Median age was 46 (IQR 41-52) years, 55% were male. Underlying disease was described, as shown in Table 1. Duration between 2 doses of CoronaVac was 21 days with median 71 (IQR 65-76) days prior to ID booster administration. The sVNT against delta strain GM was 44.5% inhibition and against wild type was 22.4% inhibition. The number of female were higher in IM cohort, while the interval between completion of 2-dose CoronaVac and AZD1222 booster was longer in ID than IM cohort.

### 3.2 Reactogenicity

Most common solicited reactogenicity reported was localized at injection site such as erythema and pain, as shown in Figure 1 and Supplementary Table 1. More than half (53%) participants reported erythema, lasting for median duration of 4 (IQR 3-6) days, which was mostly grade 1. Pain at injection site was reported in 43% with median duration of 2 (IQR 1-4) days and mostly grade 1. Other solicited reactogenicity reported were 40% fatigue, 30% myalgia, 27% headache, 18% feverish, 17% swelling, 12% arthralgia and 9% diarrhea. Vesicle and blister at injection site, which progressed to dry blister and turned to hyperpigmentation, were also reported as unsolicited reactogenicity (photo as shown in Supplementary Figure 1).

Lower systemic reactogenicity including fever (0% ID versus 27% IM, p =N/A), feverish (18% ID versus 37% IM, p = 0.003), headache (27% ID versus 64% IM, p <0.001), fatigue (40% ID versus 68% IM, p <0.001), and myalgia (30% ID versus 69% IM, p <0.001) was reported in ID compared with IM, as shown in Supplementary Table 1.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

3.3 Immunogenicity of ID booster 3.3.1 sVNT Ninety-eight percent of the participants achieved sVNT against delta strain and wild type ≥80% inhibition at both day 14 and day 28. The GMs (95% CI) of sVNT to delta strain were 95.5% inhibition (94.2-96.8) at day 14, and 93.7% inhibition (91.9-95.5) at day 28 after ID booster, as shown in Figure 2 and Table 2. The GMs (95% CI) of sVNT to wild type were 94.8% inhibition (94.0-95.6) at day 14, and 93.7% inhibition (92.1-95.4) at day 28, as shown in Table 2. At day 90 post booster vaccination, the GMs of sVNT, to both delta strain and wild type, waned to 73.1% inhibition (66.7-80.2) and 81.9% inhibition (76.2-88.0), respectively. 3.3.2 Anti-S-RBD IgG The GMs (95% CI) of anti-S-RBD IgG were 2037.1 (1770.9-2343.2), 1084.9 (970.0-1213.4), and 744.6 (650.1-852.9) BAU/mL at day 14, 28, and 90 after ID booster, respectively, as shown in Table 2. 3.4 Immunogenicity of ID compared with IM booster Proportion of participants with sVNT to delta strain ≥80% inhibition at day 14 was non-inferior among ID recipients compared with IM recipients, with difference of 4.2% (95% CI -2.0 to 10.5). But at day 90, it was significantly lower, with difference of -37.3% (-54.2 to -20.3). These differences were similar to sVNT to wild type, as shown in Table 2. GMR of anti-S-RBD IgG showed non-inferiority at day14, with GMR of 0.99 (0.83-1.20), and borderline inferior at day

90, with GMR of 0.82 (0.66-1.02). However, at 90 days after ID vaccination, only 79.5% had antibody exceeding the proposed protective level, compared with 83.8% of IM recipients.

### 3.5 T and B cell responses evaluated by ELISpot assay

From the sub study analysis of CMI response, ELISpot assay showed significant rise of T cell and B cell response at day 28 and declined at day 90, as shown in Figure 3. Median (IQR) of IFN-γ-producing T cell spots specific to SNMO protein-derived peptide pools at day 0 was 32 (14-56), at day 28 was 146 (70-192), and at day 90 was 90 (20-140) SFU/10<sup>6</sup> PBMCs, respectively. Compared with IM study, the median (IQR) was 52 (40-48) at day 0, 96 (44-128) at day 28, and 44 (32-72) SFU/10<sup>6</sup> PBMCs at day 90, respectively. Median (IQR) of RBD-specific memory B cell spots at day 0 was 2 (0-10), increased to 18 (14-36) at day 28, and declined to 6 (4-20) SFU/10<sup>6</sup> PBMCs at day 90. Compared with IM study of 4 (0-16) at day 0, 26 (16-32) at day 28, and 8 (4-16) SFU/10<sup>6</sup> PBMCs at day 90.

#### 4. Discussion

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

ID AZD1222 booster vaccine in 2-dose-CoronaVac-primed adults raised high anti-S-RBD IgG >506 BAU/ml, and high levels of functional neutralizing antibodies >80% inhibition as measured by sVNT to wild type and delta strain, thus non-inferior to IM route at day 14. However, at 3 months post ID AZD1222 booster vaccination, this study demonstrated, despite similar anti-S-RBD IgG, but lower sVNT against delta strain to IM booster, suggesting more rapid waning neutralizing antibody response after ID compared to IM route. Most reactogenicity occurred locally with erythema, pain, and swelling at injection site. Erythema, swelling, and blister were reported more common in ID booster. Systemic symptoms such as fever, feverish, headache, fatigue, and myalgia were less common than conventional IM injection. The non-inferior immunogenicity of ID vaccination was demonstrated for influenza, rabies, and hepatitis B vaccines [21]. Immunogenicity of ID AZD1222 at day 14 was not inferior to conventional IM booster vaccine as shown with GMR of anti-S-RBD and difference in proportion of participants having sVNT to delta strain and wild type passing 80%. This comparable result is similar to previous study in Netherland [22] which reported a robust antibody response from ID administration of mRNA COVID-19 vaccine at day 43 with comparable anti-spike IgG response for 10 µg ID with 100 µg IM mRNA-1273 vaccine. Additionally, recent report from Thailand also denoted a fractional-dose BNT162b2 ID booster, in healthy adults who had completed 2-dose inactivated vaccine for 2-3 months, induced comparable antibody level and function to the conventional IM booster when assessed on day 14 and 28 [14]. To our knowledge, no published report demonstrated immunogenicity results at 3 months post ID AZD1222 booster vaccination, which this study demonstrated inferior neutralizing antibodies.

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

Although, the importance of cellular immunity in correlation with vaccine protection is still unclear, specific T cells have been reported to reduce the severity of SARS-CoV-2 infection [23]. In this study, we have shown that a third dose of ID AZD1222 booster vaccine can increase specific T cell responses slightly higher than conventional IM route, similar to the previous report [24]. As opposed to previous ID BNT162b2 study, which failed to demonstrate T cell response, suggesting different vaccine platforms might play a role in cellular immune response. Specific memory B cells also have been reported to play a crucial role for effective responses to infection [25, 26]. Our result showed the slight boost of B cell response at 1 month and drop at 3 months, after ID AZD1222 booster. The timing of B cell study might be accounted for these responses, since the previous study showed the detectable B cell response after COVID-19 infection for 3-6 months [27]. This study reported local reactogenicity including erythema, blister, and pruritus after ID AZD1222 booster vaccine which is similar to previous report on rabies inactivated vaccine that more erythema and pruritus were reported from ID than conventional IM administration [28]. Also blister formation was reported after BCG vaccination that evolved over two weeks into an ulcer at injection site [29]. ID influenza vaccine study reported significant higher local adverse events particularly erythema and swelling, and also more common of fever and chills which is different from this study that fever was more common in IM vaccination [9]. Hyperpigmentation was also reported in this study as still seen on day 28 follow up visit which previous study of hepatitis B vaccine reported of local hyperpigmentation after ID vaccination in 55% [30]. Compared with parallel cohort IM study, ID booster had more local reactogenicity (erythema and swelling) at injection site but less pain and systemic reactogenicity (fatigue, myalgia, headache, feverish, arthralgia and diarrhea).

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

As current situation of COVID-19 pandemic, more vaccine supply is still needed for many countries as vaccine coverage is not enough to prevent mortality [31-33]. Almost half of the world population has received at least one dose of COVID-19 vaccine but only 2.2% of people in low-income countries have received vaccine [34]. AZD1222 or Astra Zeneca/Oxford COVID-19 vaccine has been used in Europe since December 2020 and also distributed in many countries including low to middle income countries [35]. As availability in many countries with limited vaccine supply, the ID administration of AZD1222 might be considered for mass vaccination as an advantage of dose-sparing technique [7]. However, there are some limitations, needs of skilled health providers for administration [36], and more rapid waning of neutralizing antibodies. This study was limited by cohort study design without randomized control trial but there was the parallel cohort study with similar setting that should be able to benchmark the results. There were 2 factors that differed between the 2 groups. Specifically, there was more male in the ID group and the time interval between second and third dose was 1 week longer in the ID group. However, the immune responses at baseline before the third dose were comparable. Female was reported to have higher antibody response to vaccines [37] and after severe COVID-19 [38]. The finding of later inferior neutralizing antibodies might be attributed to this gender difference, specifically more male participants in ID cohort. This study chose to determine the levels of functional neutralizing antibodies using the surrogate virus neutralization assay, rather than standard live-virus neutralization assay. However, we used the high cut-off value at 80% of sVNT in this study. Moreover, good correlations between sVNT and live-virus neutralization have been exhibited elsewhere [18, 39-41]. The strengths of this study were reporting complete solicited reactogenicity of all 100 participants with ID booster vaccination and multiple methods

were used for immunity analysis including anti-S-RBD, sVNT (wild type and delta strain) and also CMI responses.

Intradermal AZD1222 booster vaccine in 2-dose-CoronaVac primed adult enhanced comparable short-term immunity, but inferior 3-month immunogenicity, with intramuscular administration. Reactogenicity was usually localized (erythema and pain) and less systemic than intramuscular vaccine. Due to more rapid waning neutralizing antibody, dose-sparing strategy with intradermal booster vaccination should be used in the setting of inadequate vaccine supply.

382 Acknowledgements 383 Thank you for all study teams for their assistance with the study. 384 Chulalongkorn University Health Service Center 385 Santhiti Dahlan, M.D., Preeyanuch Panchim, Ratchadaporn Bumrungpipattanaporn, RN, 386 Ampawan Sangchanpong, Wijitra Prayong 387 Department of Microbiology, Faculty of Medicine, Chulalongkorn University 388 Asst. Prof. Pokrath Hansasuta, M.D., Vichaya Ruenjaiman, PhD, Supapit Horpratum, 389 Jullada Thawilwang 390 Center of Excellence in Pediatric Infectious Diseases and Vaccines 391 Pintip Suchartlikitwong, M.D., Wipaporn Natalie Songtaweesin, M.D., Pathariya 392 Promsena, M.D., Monta Tawan, RN, Jitthiwa Athipunjapong, RN, Thutsanun 393 Meepuksom, RN, Angsumalin Sutjarit, RN, Juthamanee Moonwong, Rachaneekorn 394 Nadsasarn, Thidarat Jupimai, Pornpavee Nuncharoen, Sasiprapha Khamthi, Pathomchai 395 Amornrattanapaijit, Phattharapa Khamkhen, 396 National Center for Genetic Engineering and Biotechnology (BIOTEC) 397 Anan Jongkaewwattana, PhD, Kirana Yoohat, Channarong Seepiban, Jaraspim Narkpuk, 398 Thorntun Deangphare, 399 Clinical Research Laboratory, Faculty of Medicine, Chulalongkorn University 400 Palida Pingthaisong, Suwat Wongmueng 401 Faculty of Medicine, Thammasat University 402 Asst.Prof.Sira Nantapisal, M.D., Ph.D. 403 404 **Funding** 

The study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under

Health Research Platform (RA64/050), Chulalongkorn University. This research is also
supported by Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn
University.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

# **Table 1.** Baseline characteristics of participants receiving AZD1222 booster vaccine after 2-dose

## CoronaVac in healthy adults

414

Characteristic	ID (N = 100)	IM (N = 100)	p-value
Gender			
• Female, n (%)	45 (45)	61 (61)	$0.02^{\dagger *}$
Age (years)	46 (41-52)	45 (34-50)	$0.08^{\ddagger}$
BMI (kg/m <sup>2</sup> )	24.8 (21.4-27.4)	24.1 (21.6-26.9)	0.37‡
Underlying disease, n (%)	19 (19)	29 (29)	$0.10^{\dagger}$
• Hypertension, n (%)	7 (7)	9 (9)	$0.60^{\dagger}$
• Dyslipidemia, n (%)	6 (6)	7 (7)	$0.77^{\dagger}$
• Diabetes mellitus, n (%)	6 (6)	3 (3)	$0.31^{\dagger}$
• Allergic rhinitis, n (%)	1 (1)	2 (2)	$0.56^{\dagger}$
Duration of 2 <sup>nd</sup> doses of CoronaVac and	71 (65 76)		0.002 <sup>‡</sup> *
AZD1222 (days)	71 (65-76)	66 (62-74)	
Immunogenicity at baseline prior to booster			
• sVNT-delta (% inhibition), GM (95%CI)	22.4 (18.7-26.9)	17.9 (14.3-22.5)	0.14 <sup>§</sup>
• sVNT-WT (%inhibition), GM (95%CI)	44.5 (40.6-48.7)	41.8 (37.1-47.1)	0.41§
• Anti-S-RBD (BAU/mL), GM (95%CI)	109.3 (95.4-125.1)	98.9 (85.8-113.9)	0.31§
SNMO-specific T cell response	32 (14-56)	52 (40-84)	0.05 <sup>‡</sup>
(SFU/10 <sup>6</sup> PBMCs)	(n = 20)	(n = 19)	0.05
RBD-specific B cell response	2 (0-10)	4 (0-16)	÷
(SFU/10 <sup>6</sup> PBMCs)	(n = 20)	(n = 19)	$0.50^{\ddagger}$

All data are reported as median (IQR), unless otherwise indicated.

417 Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, BMI: Body 418 mass index, GM: Geometric mean, ID: intradermal, IM: intramuscular, IQR: interquartile range, 419 RBD: receptor binding domain, SNMO: Spike (S) nucleoprotein (N), membrane protein (M), 420 and open reading frame proteins (O) of SARS-CoV-2, sVNT-delta: Surrogate virus 421 neutralization test against delta strain, sVNT-WT: Surrogate virus neutralization test against wild 422 type 423 <sup>†</sup>Chi-square 424 <sup>‡</sup>Wilcoxon rank sum test 425 Two sample independent t test 426 p < 0.05

# Table 2. Comparison of intradermal and intramuscular AZD1222 booster immunogenicity in


# healthy adult completing 2-dose CoronaVac

427

	ID	IM	GM Ratio
	GM (95%CI)	GM (95%CI)	(95%CI)
Day 14	N=50	N=100	
<ul> <li>Anti-S-RBD (BAU/mL)</li> </ul>	2037.1	2043.2	0.99
- Time S RDD (Bric/inc)	(1770.9-2343.2)	(1824.5-2288.2)	(0.83-1.20)
<ul> <li>sVNT-Delta (% inhibition)</li> </ul>	95.5	94.7	1.01
	(94.2-96.8)	(92.4-97.1)	(0.97-1.04)
• sVNT-WT (% inhibition)	94.8	96.7	0.98
	(94.0-95.6)	(94.9-98.4)	(0.96-1.01)
Day 28	N=50	N=24	
Anti-S-RBD (BAU/mL)	1084.9	1499.5	0.72
That is reported the first the state of the	(970-1213.4)	(1166.6-1927.4)	(0.57 - 0.91)
• sVNT-Delta (% inhibition)	93.7	88.5	1.06
5 SVIVI Delta (70 Infibition)	(91.9-95.5)	(80.1-97.7)	(0.99-1.14)
• sVNT-WT (% inhibition)	93.7	91.5	1.02
5 SVIVI WI (// Infilolation)	(92.1-95.4)	(85.9-97.4)	(0.98-1.08)
Day 90	N=39	N=99	
Anti-S-RBD (BAU/mL)	744.6	909	0.82
7 min 5 RDD (B/10/mil)	(650.1-852.9)	(802.1-1030.1)	(0.66-1.02)
• sVNT-Delta (% inhibition)	73.1	92.8	0.79
• sVNT-Delta (% inhibition)	(66.7-80.2)	(90.2-95.4)	(0.73-0.85)
• sVNT-WT (% inhibition)	81.9	94.6	0.87
SVIVI-WI (// minoruon)	(76.2-88.0)	(92.4-96.9)	(0.82 - 0.92)
	% (95%CI)	% (95%CI)	% difference (95%CI)
Day 14	N=50	N=100	
• Anti-S-RBD ≥ 506 BAU/ml <sup>†</sup>	100.0	97.0	3.0
• Anti-5-RBD 2 506 BAU/mi	(92.8-100.0)	(91.5-99.4)	(-0.3  to  6.3)
• sVNT-Delta ≥ 80% inhibition	98.0	93.8	4.2
SVIVI-Delta 2 00 /0 minorition	(89.1-99.9)	(86.9-97.6)	(-2.0 to 10.5)
• sVNT-WT ≥ 80% inhibition	100.0	95.8	4.2
SVIVI-W1 2 8070 Inhibition	(92.8-100.0)	(89.7-98.9)	(0.01 to 8.2)
Day 28	N=50	N=24	
• Anti-S. RRD > 506 RAII/ml†	-RBD ≥ 506 BAU/ml <sup>†</sup> 98.0 96.0 2.0 (70.4.00.0) (70.6.00.0)		
- Aliu-5-KDD 2 300 DAO/IIII	(89.4-99.9)	<del>,</del> , , , , , , , , , , , , , , , , , ,	
• sVNT-Delta ≥ 80% inhibition	98.0	91.7	6.3

	(89.4-99.9)	(73.0-98.9)	(-5.4 to 18.1)
• sVNT-WT ≥ 80% inhibition	98.0	91.7	6.3
	(89 4-99 9)	(73.0-98.9)	(-5.4 to 18.1)
Day 90	N=39	N=99	
• Anti-S-RBD ≥ 506 BAU/ml <sup>†</sup>	79.5	83.8	-4.4
	(63.5-90.7)	(75.1-90.5)	(-18.9 to 10.2)
• sVNT-Delta ≥ 80% inhibition	52.6	89.9	-37.3
	(35.8-69)	(82.2-95)	(-54.2 to -20.3)
• sVNT-WT ≥ 80% inhibition	68.4	90.9	-22.5
	(51.3-82.5)	(83.4-95.7)	(-38.3 to -6.7)

Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, GM: Geometric mean, ID: intradermal, IM: intramuscular, sVNT-delta: Surrogate virus neutralization test against delta strain, sVNT-WT: Surrogate virus neutralization test against wild type <sup>†</sup>Anti-S-RBD IgG 506 BAU/ml correlated with 80% vaccine efficacy as reported by Feng, et al [17].



**Figure** 1. Solicited reactogenicity within 7 days of ID and IM AZD1222 booster after 2-dose CoronaVac in healthy adult.


ID intradermal, IM intramuscular

437

438

439

440



443

444

445


446

447

**Figure 2.** Comparison of sVNT % inhibition against delta strain at day 0, 14, 28, and 90 of ID and IM AZD1222 booster after 2-dose of CoronaVac in healthy adult.

ID: intradermal, IM: intramuscular, sVNT: Surrogate virus neutralization test

# 448 (A) SNMO-specific T cell response



## 450 (B) RBD-specific B cell response

449




Figure 3. ELISpot assay at day 0, day 28, and day 90 of ID and IM AZD1222 booster in healthy adult completing 2-dose CoronaVac: (A) Interferon-γ ELISpot response to SNMO overlapping peptides of SARS-CoV-2, (B) RBD-specific IgG ELISpot assay.

ID: intradermal, IM: intramuscular, RBD: receptor binding domain, SFU: spot forming unit, SNMO: Spike (S) nucleoprotein (N), membrane protein (M), and open reading frame proteins (O) of SARS-CoV-2

# Supplementary Table 1. Solicited reactogenicity within 7 days of ID and IM AZD1222 booster

## after 2-dose CoronaVac in healthy adult.

460

Local reactogenicity	Reactogenicity, n (%)	ID	IM	P-value
Pain         43 (43)         82 (82)         <0.001*		(N=100)	(N=100)	
• Mild         41 (41)         67 (67)           • Moderate         2 (2)         13 (13)           • Severe         0         2 (2)           • Duration (days), median (IQR)         2 (1-4)         3 (2-5)         0.12           Swelling         17 (17)         3 (3)         0.002*           • Mild         15 (15)         1 (1)         2 (2)           • Moderate         1 (1)         2 (2)         2 (2)           • Severe         1 (1)         0         0         2 (2)           • Duration (days), median (IQR)         6 (5-8)         4 (3-6)         0.28         0.28           Redness         53 (53)         3 (3)         <0.001*          0 (0)         0	Local reactogenicity			
• Moderate         2 (2)         13 (13)           • Severe         0         2 (2)           • Duration (days), median (IQR)         2 (1-4)         3 (2-5)         0.12           Swelling         17 (17)         3 (3)         0.002*           • Mild         15 (15)         1 (1)         2 (2)           • Moderate         1 (1)         0         2 (2)           • Severe         1 (1)         0         2 (2)           • Duration (days), median (IQR)         6 (5-8)         4 (3-6)         0.28           Redness         53 (53)         3 (3)         <0.001*           • Mild         47 (47)         0 (0)         0	Pain	43 (43)	82 (82)	<0.001*
<ul> <li>Severe 0 2 (2)</li> <li>Duration (days), 2 (1-4) 3 (2-5) 0.12</li> <li>Buration (IQR)</li> <li>Mild 15 (15) 1 (1)</li> <li>Moderate 1 (1) 2 (2)</li> <li>Severe 1 (1) 0</li> <li>Duration (days), 6 (5-8) 4 (3-6) 0.28</li> <li>Mild 47 (47) 0 (0)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Duration (days), 4 (3-6) 5 (1-6) 0.35</li> <li>Mild 47 (47) 0 (0)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Duration (days), 4 (3-6) 5 (1-6) 0.35</li> <li>Mild 0 10 (10)</li> <li>Moderate 0 12 (12)</li> <li>Severe 0 5 (5)</li> <li>Duration (days), - 2 (1-2) NA</li> <li>Moderate 0 12 (12)</li> <li>Severe 0 5 (5)</li> <li>Duration (days), - 2 (1-2) NA</li> <li>Mild 16 (16) 27 (27)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), 1 (1-2) 1 (1-2) 0.93</li> <li>median (IQR)</li> <li>Medache 27 (27) 64 (64) &lt;0.001*</li> <li>Mild 17 (17) 37 (37)</li> </ul>	• Mild	41 (41)	67 (67)	
<ul> <li>Duration (days), median (IQR)</li> <li>Swelling</li> <li>17 (17)</li> <li>3 (3)</li> <li>0.002*</li> <li>Mild</li> <li>15 (15)</li> <li>1 (1)</li> <li>Moderate</li> <li>1 (1)</li> <li>Severe</li> <li>1 (1)</li> <li>Duration (days), median (IQR)</li> <li>Mild</li> <li>47 (47)</li> <li>0 (0)</li> <li>Moderate</li> <li>5 (5)</li> <li>2 (2)</li> <li>Severe</li> <li>1 (1)</li> <li>Mild</li> <li>47 (47)</li> <li>0 (0)</li> <li>Moderate</li> <li>5 (5)</li> <li>2 (2)</li> <li>Severe</li> <li>1 (1)</li> <li>1 (1)</li> <li>Duration (days), median (IQR)</li> <li>Systemic reactogenicity</li> <li>Fever (BT≥38°C)</li> <li>Mild</li> <li>10 (10)</li> <li>Moderate</li> <li>Severe</li> <li>12 (12)</li> <li>Severe</li> <li>Duration (days), median (IQR)</li> <li>18 (18)</li> <li>27 (27)</li> <li>MA</li> <li>Mild</li> <li>16 (16)</li> <li>27 (27)</li> <li>Moderate</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Moderate</li> <li>10 (10)</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Feverish</li> <li>Mild</li> <li>16 (16)</li> <li>27 (27)</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Mild</li> <li>16 (16)</li> <li>27 (27)</li> <li>46 (64)</li> <li>40.001*</li> <li>Mild</li> <li>17 (17)</li> <li>37 (37)</li> </ul>	<ul> <li>Moderate</li> </ul>	2 (2)	13 (13)	
median (IQR)         Swelling       17 (17)       3 (3)       0.002*         • Mild       15 (15)       1 (1)          • Moderate       1 (1)       2 (2)          • Severe       1 (1)       0  <	<ul> <li>Severe</li> </ul>	0	2 (2)	
Swelling         17 (17)         3 (3)         0.002*           • Mild         15 (15)         1 (1)           • Moderate         1 (1)         2 (2)           • Severe         1 (1)         0           • Duration (days), median (IQR)         6 (5-8)         4 (3-6)         0.28           Redness         53 (53)         3 (3)         <0.001*	• Duration (days),	2 (1-4)	3 (2-5)	0.12
<ul> <li>Mild</li> <li>Moderate</li> <li>1 (1)</li> <li>Severe</li> <li>1 (1)</li> <li>Q (2)</li> <li>Severe</li> <li>1 (1)</li> <li>0</li> <li>Duration (days), and (days), and (days), and (days), and (days), and (days)</li> <li>Mild</li> <li>Mild</li> <li>Moderate</li> <li>5 (5)</li> <li>2 (2)</li> <li>Severe</li> <li>1 (1)</li> <li>Duration (days), and (days), and (days)</li> <li>Mild</li> <li>Moderate</li> <li>5 (5)</li> <li>2 (2)</li> <li>Severe</li> <li>1 (1)</li> <li>1 (1)</li> <li>MA</li> <li>Mild</li> <li>0</li> <li>10 (10)</li> <li>Moderate</li> <li>0</li> <li>12 (12)</li> <li>Severe</li> <li>0</li> <li>5 (5)</li> <li>Duration (days), and (days), and (days), and (days), and (days), and (days)</li> <li>Mild</li> <li>16 (16)</li> <li>27 (27)</li> <li>Moderate</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Duration (days), and (days)</li> <li>Mild</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Duration (days), and (days), and (days)</li> <li>Mild</li> <li>Moderate</li> <li>27 (27)</li> <li>64 (64)</li> <li>0.001*</li> <li>Mild</li> <li>Headache</li> <li>27 (27)</li> <li>64 (64)</li> <li>0.001*</li> </ul>	median (IQR)			
<ul> <li>Moderate 1 (1) 2 (2)</li> <li>Severe 1 (1) 0</li> <li>Duration (days), median (IQR)</li> <li>Mild 47 (47) 0 (0)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Duration (days), median (IQR)</li> <li>Mild 0 10 (10)</li> <li>Moderate 0 27 (27) NA</li> <li>Mild 0 10 (10)</li> <li>Moderate 0 12 (12)</li> <li>Severe 0 1 (1) 10 (10)</li> <li>Moderate 0 12 (12)</li> <li>Severe 1 (10) 10 (10)</li> <li>Moderate 1 (10) 10 (10)</li> <li>Moderate 1 (10) 10 (10)</li> <li>Moderate 2 (10) 10 (10)</li> <li>Moderate 1 (10) 10 (10)</li> <li>Moderate 2 (10) 10 (10)</li> <li>Moderate 1 (10) 10 (10)</li> <li>Moderate 2 (10) 10 (10)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Duration (days), median (IQR)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Mild 16 (16) 27 (27)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Mild 17 (17) 37 (37)</li> </ul>	Swelling	17 (17)	3 (3)	0.002*
<ul> <li>Severe 1 (1) 0</li> <li>Duration (days), median (IQR)</li> <li>Redness 53 (53) 3 (3) &lt;0.001*</li> <li>Mild 47 (47) 0 (0)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Duration (days), median (IQR)</li> <li>Systemic reactogenicity</li> <li>Fever (BT≥38°C) 0 27 (27) NA</li> <li>Mild 0 10 (10)</li> <li>Moderate 0 12 (12)</li> <li>Severe 0 5 (5)</li> <li>Duration (days), additional median (IQR)</li> <li>Mild 0 10 (10)</li> <li>Moderate 0 5 (5)</li> <li>Duration (days), and median (IQR)</li> <li>Feverish 18 (18) 37 (37) 0.003*</li> <li>Mild 16 (16) 27 (27)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Mild 16 (16) 27 (27)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Mild 16 (16) 27 (27)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Mild 17 (17) 37 (37)</li> </ul>	• Mild	15 (15)	1 (1)	
• Duration (days), median (IQR)       6 (5-8)       4 (3-6)       0.28         • Mild (IQR)       47 (47)       0 (0)         • Mild (IQR)       47 (47)       0 (0)         • Moderate (IQR)       5 (5)       2 (2)         • Severe (ID)       1 (1)       1 (1)         • Duration (days), median (IQR)       4 (3-6)       5 (1-6)       0.35         • Systemic reactogenicity       5 (1-6)       0.35         • Mild (ID)       0 (ID)       0.000       0.000         • Mild (ID)       0 (ID)       0.000       0.000       0.000         • Duration (days), median (IQR)       - (ID)       0.000<	Moderate	1 (1)	2 (2)	
Redness       53 (53)       3 (3)       <0.001*         • Mild       47 (47)       0 (0)         • Moderate       5 (5)       2 (2)         • Severe       1 (1)       1 (1)         • Duration (days), median (IQR)       4 (3-6)       5 (1-6)       0.35         Systemic reactogenicity         Fever (BT≥38°C)       0       27 (27)       NA         • Mild       0       10 (10)         • Moderate       0       12 (12)         • Severe       0       5 (5)         • Duration (days), median (IQR)       -       2 (1-2)       NA         Feverish       18 (18)       37 (37)       0.003*         • Mild       16 (16)       27 (27)       0.003*         • Moderate       2 (2)       10 (10)         • Duration (days), median (IQR)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*         • Mild       17 (17)       37 (37)	• Severe	1 (1)	0	
Redness       53 (53)       3 (3)       <0.001*         • Mild       47 (47)       0 (0)         • Moderate       5 (5)       2 (2)         • Severe       1 (1)       1 (1)         • Duration (days), median (IQR)       4 (3-6)       5 (1-6)       0.35         Systemic reactogenicity         Fever (BT≥38°C)       0       27 (27)       NA         • Mild       0       10 (10)         • Moderate       0       12 (12)         • Severe       0       5 (5)         • Duration (days), median (IQR)       -       2 (1-2)       NA         Feverish       18 (18)       37 (37)       0.003*         • Mild       16 (16)       27 (27)       0.003*         • Mild       16 (16)       27 (27)       0.93         median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	Duration (days),	6 (5-8)	4 (3-6)	0.28
<ul> <li>Mild 47 (47) 0 (0)</li> <li>Moderate 5 (5) 2 (2)</li> <li>Severe 1 (1) 1 (1)</li> <li>Duration (days), and (ays), median (IQR)</li> <li>Systemic reactogenicity</li> <li>Mild 0 10 (10)</li> <li>Moderate 0 12 (12)</li> <li>Severe 0 5 (5)</li> <li>Duration (days), and (days), and (days), and (days), and (days), and (days)</li> <li>Mild 16 (16) 27 (27)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), and (days)</li> <li>Mild 16 (16) 27 (27)</li> <li>Moderate 2 (2) 10 (10)</li> <li>Duration (days), and (days), and (days)</li> <li>Mild 17 (17) 37 (37)</li> </ul>	median (IQR)			
<ul> <li>Moderate</li> <li>Severe</li> <li>1 (1)</li> <li>Duration (days), and (days), median (IQR)</li> <li>Systemic reactogenicity</li> <li>Mild</li> <li>Moderate</li> <li>Moderate</li> <li>Moderate</li> <li>Severe</li> <li>10 (10)</li> <li>Moderate</li> <li>Severe</li> <li>10 (10)</li> <li>Severe</li> <li>12 (12)</li> <li>Severe</li> <li>10 (10)</li> <li>Moderate</li> <li>12 (12)</li> <li>Severe</li> <li>Moderate</li> <li>Moderate</li> <li>Moderate</li> <li>Mild</li> <li>Moderate</li> <li>Moderate<!--</td--><td>Redness</td><td>53 (53)</td><td>3 (3)</td><td>&lt;0.001*</td></li></ul>	Redness	53 (53)	3 (3)	<0.001*
<ul> <li>Severe 1 (1) 1 (1)</li></ul>	• Mild	47 (47)	0 (0)	
<ul> <li>Duration (days), median (IQR)</li> <li>Systemic reactogenicity</li> <li>Fever (BT≥38°C)</li> <li>Mild</li> <li>Moderate</li> <li>Severe</li> <li>Severe</li> <li>Duration (days), median (IQR)</li> <li>Mild</li> <li>10 (10)</li> <li>Severe</li> <li>Severe</li> <li>2 (1-2)</li> <li>NA</li> <li>Duration (days), median (IQR)</li> <li>Mild</li> <li>16 (16)</li> <li>27 (27)</li> <li>Moderate</li> <li>2 (2)</li> <li>10 (10)</li> <li>Duration (days), median (IQR)</li> <li>Duration (days), median (IQR)</li> <li>Mild</li> <li>17 (17)</li> <li>37 (37)</li> </ul>	Moderate	5 (5)	2 (2)	
Systemic reactogenicity         Fever (BT≥38°C)       0       27 (27)       NA         • Mild       0       10 (10)         • Moderate       0       12 (12)         • Severe       0       5 (5)         • Duration (days), median (IQR)       -       2 (1-2)       NA         Feverish       18 (18)       37 (37)       0.003*         • Mild       16 (16)       27 (27)         • Moderate       2 (2)       10 (10)         • Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	• Severe	1 (1)	1 (1)	
Systemic reactogenicity         Fever (BT≥38°C)       0       27 (27)       NA         • Mild       0       10 (10)         • Moderate       0       12 (12)         • Severe       0       5 (5)         • Duration (days), median (IQR)       -       2 (1-2)       NA         Feverish       18 (18)       37 (37)       0.003*         • Mild       16 (16)       27 (27)         • Moderate       2 (2)       10 (10)         • Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	• Duration (days),	4 (3-6)	5 (1-6)	0.35
Fever (BT≥38°C)       0       27 (27)       NA         • Mild       0       10 (10)         • Moderate       0       12 (12)         • Severe       0       5 (5)         • Duration (days), median (IQR)       -       2 (1-2)       NA         Feverish       18 (18)       37 (37)       0.003*         • Mild       16 (16)       27 (27)         • Moderate       2 (2)       10 (10)         • Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	median (IQR)			
<ul> <li>Mild</li></ul>	Systemic reactogenicity			
<ul> <li>Moderate</li> <li>Severe</li> <li>Severe</li> <li>Duration (days), and median (IQR)</li> <li>Mild</li> <li>Moderate</li> <li>Moderate</li> <li>Moderate</li> <li>Duration (days), and median (IQR)</li> <li>Moderate</li> <li>Moderate</li> <li>Duration (days), and median (IQR)</li> <li>Median (IQR)</li> <li>Median (IQR)</li> <li>Moderate</li> <li< td=""><td>Fever (BT≥38°C)</td><td>0</td><td>27 (27)</td><td>NA</td></li<></ul>	Fever (BT≥38°C)	0	27 (27)	NA
◆ Severe       0       5 (5)         • Duration (days), median (IQR)       -       2 (1-2)       NA         Feverish       18 (18)       37 (37)       0.003*         • Mild       16 (16)       27 (27)         • Moderate       2 (2)       10 (10)         • Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*         • Mild       17 (17)       37 (37)	• Mild	0	10 (10)	
● Duration (days), median (IQR)       -       2 (1-2)       NA         Feverish       18 (18)       37 (37)       0.003*         ● Mild       16 (16)       27 (27)         ● Moderate       2 (2)       10 (10)         ● Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	Moderate	0	12 (12)	
median (IQR)         Feverish       18 (18)       37 (37)       0.003*         ● Mild       16 (16)       27 (27)         ● Moderate       2 (2)       10 (10)         ● Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	• Severe	0	5 (5)	
median (IQR)         Feverish       18 (18)       37 (37)       0.003*         ● Mild       16 (16)       27 (27)         ● Moderate       2 (2)       10 (10)         ● Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	Duration (days),	-	2 (1-2)	NA
● Mild       16 (16)       27 (27)         ● Moderate       2 (2)       10 (10)         ● Duration (days), median (IQR)       1 (1-2)       1 (1-2)         Headache       27 (27)       64 (64)       <0.001*	median (IQR)			
● Moderate       2 (2)       10 (10)         ● Duration (days), median (IQR)       1 (1-2)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*         ● Mild       17 (17)       37 (37)	Feverish	18 (18)	37 (37)	0.003*
● Duration (days), median (IQR)       1 (1-2)       0.93         Headache       27 (27)       64 (64)       <0.001*	• Mild	16 (16)	27 (27)	
median (IQR)  Headache 27 (27) 64 (64) <0.001*  ● Mild 17 (17) 37 (37)	Moderate	2 (2)	10 (10)	
Headache       27 (27)       64 (64)       <0.001*         ● Mild       17 (17)       37 (37)	• Duration (days),	1 (1-2)	1 (1-2)	0.93
• Mild 17 (17) 37 (37)	median (IQR)			
	Headache	27 (27)	64 (64)	<0.001*
• Moderate 10 (10) 24 (24)	• Mild	17 (17)	37 (37)	
	Moderate	10 (10)	24 (24)	


• Sever	e	0	3 (3)	
• Durat	ion (days),	2 (1-2)	2 (1-3)	0.15
media	ın (IQR)			
Fatigue		40 (40)	68 (68)	<0.001*
• Mild		36 (36)	42 (42)	
<ul> <li>Mode</li> </ul>	rate	4 (4)	22 (22)	
<ul> <li>Sever</li> </ul>	e	0 (0)	4 (4)	
	ion (days), nn (IQR)	1 (1-2)	2 (2-3)	0.61
Myalgia		30 (30)	69 (69)	<0.001*
• Mild		27 (27)	35 (35)	
• Mode	rate	3 (3)	31 (31)	
• Sever	e	0 (0)	3 (3)	
	ion (days),	2 (2-3)	2 (2-3)	0.60
media	ın (IQR)			
Arthralgia		12 (12)	21 (21)	0.09
• Mild		8 (8)	15 (15)	
• Mode	rate	4 (4)	5 (5)	
<ul> <li>Sever</li> </ul>	e	0 (0)	1 (1)	
<ul> <li>Durat</li> </ul>	ion (days),	2 (2-3)	2 (1-2)	0.06
media	ın (IQR)			
Vomiting		0	4 (4)	NA
• Mild		0	4 (4)	
• Mode	rate	0	0 (0)	
• Sever		0	0 (0)	
	ion (days),	0	1 (1-1)	NA
media	ın (IQR)			
Diarrhea		9 (9)	12 (12)	0.49
• Mild		8 (8)	11 (11)	
• Mode		1 (1)	1 (1)	
	ion (days), ın (IQR)	1 (1-3)	1 (1-2)	0.43

ID: intradermal, IM: intramuscular

464 \*p < 0.05

462

463





**Supplementary Figure 1.** Photography of local reactogenicity in participants receiving intradermal AZD1222 booster after completing 2-dose CoronaVac: (A) local reactogenicity in participants: i-ii) erythematous patch at injection site at day 4, iii) residual post inflammatory

468

469

hyperpigmented macule and iv) erythematous patch at injection site at day 28 and (B) a serial photography day 1-7 in single participant: Day 1 erythematous patch at injection site, Day 2 central swelling on erythematous patch, Day 3-6 blister forming at central of erythematous patch, and Day 7 dry blister with necrotic crust on erythematous base.

#### References

- 476 1. WHO. WHO Coronavirus (COVID-19) Dashboard [Available from:
- https://covid19.who.int/. Accessed date 28 November, 2021.
- 478 2. Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness
- of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med 2021.
- 480 https://doi.org/10.1056/NEJMoa2107715
- 481 3. Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al.
- 482 Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
- 483 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg
- 484 Health Am 2021:100025. https://doi.org/10.1016/j.lana.2021.100025
- 485 4. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T,
- 486 Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of concern
- 487 than natural infection. Lancet Infect Dis 2021. https://doi.org/10.1016/S1473-3099(21)00568-5
- Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
- immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral
- 490 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-
- 491 inferiority trial. Lancet 2021;398:856-69. https://doi.org/10.1016/S0140-6736(21)01694-9
- 492 6. Benning L, Tollner M, Hidmark A, Schaier M, Nusshag C, Kalble F, et al. Heterologous
- 493 ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses
- among Health Care Workers. Vaccines (Basel) 2021;9. https://doi.org/10.3390/vaccines9080857
- 495 7. Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal Vaccination:
- 496 A Potential Tool in the Battle Against the COVID-19 Pandemic? Risk Manag Healthc Policy
- 497 2021;14:2079-87. https://doi.org/10.2147/RMHP.S309707

- 498 8. Hettinga J, Carlisle R. Vaccination into the Dermal Compartment: Techniques,
- 499 Challenges, and Prospects. Vaccines (Basel) 2020;8. https://doi.org/10.3390/vaccines8030534
- 500 9. Egunsola O, Clement F, Taplin J, Mastikhina L, Li JW, Lorenzetti DL, et al.
- 501 Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines:
- A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4:e2035693.
- 503 https://doi.org/10.1001/jamanetworkopen.2020.35693
- 504 10. World Health O. Polio vaccines: WHO position paper, March 2016-recommendations.
- 505 Vaccine 2017;35:1197-9. https://doi.org/10.1016/j.vaccine.2016.11.017
- 506 11. World Health O. WHO Expert Consultation on Rabies. Second report. World Health
- 507 Organ Tech Rep Ser 2013:1-139, back cover.
- 508 12. World Health O. Rabies vaccines: WHO position paper, April 2018 Recommendations.
- 509 Vaccine 2018;36:5500-3. https://doi.org/10.1016/j.vaccine.2018.06.061
- 510 13. Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al.
- Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273
- 512 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv
- 513 2021:2021.07.27.21261116. https://doi.org/10.1101/2021.07.27.21261116
- 514 14. Intapiboon PS, P.; Ongarj, J.; Surasombatpattana, S.; Uppanisakorn, S.;
- Mahasirimongkol, S.; Sawaengdee, W.; Phumiamorn, S.; Sapsutthipas, S.; Sangsupawanich, P.;
- 516 Chusri, S.; Pinpathomrat, N. Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
- Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.
- 518 Vaccines 2021. https://doi.org/10.3390/vaccines9121375

- 519 15. Singhatiraj E, Pongpirul K, Jongkaewwattana A, Hirankarn N. Intradermal ChAdOx1
- Vaccine Following Two CoronaVac Shots: A Case Report. Vaccines 2021;9:990.
- 521 https://doi.org/10.3390/vaccines9090990
- 522 16. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et
- al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med
- 524 2020;26:1033-6. https://doi.org/10.1038/s41591-020-0913-5
- 525 17. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
- against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021.
- 527 https://doi.org/10.1038/s41591-021-01540-1
- 528 18. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus
- neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein
- interaction. Nat Biotechnol 2020;38:1073-8. https://doi.org/10.1038/s41587-020-0631-z
- 531 19. U.S. Department of Health and Human Services F, CBER. Guidance for Industry
- Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive
- Vaccine Clinical Trials September 2007 [Available from:
- https://www.fda.gov/media/73679/download. Accessed date 30 November, 2021.
- 535 20. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
- against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine 2021.
- 537 https://doi.org/10.1038/s41591-021-01540-1
- 538 21. Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijnis C, et al.
- 539 Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination A
- 540 systematic review and meta-analysis. Travel Med Infect Dis 2020;37:101868.
- 541 https://doi.org/10.1016/j.tmaid.2020.101868

- 542 22. Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al.
- Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273
- 544 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021.
- 545 https://doi.org/10.1101/2021.07.27.21261116
- Noh JY, Jeong HW, Kim JH, Shin EC. T cell-oriented strategies for controlling the
- 547 COVID-19 pandemic. Nat Rev Immunol 2021. https://doi.org/10.1038/s41577-021-00625-9
- 548 24. Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, et al.
- Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific
- 550 Immune Response. Front Immunol 2021;12:645210. https://doi.org/10.3389/fimmu.2021.645210
- 551 25. Jahnmatz P, Sundling C, Makower B, Sonden K, Farnert A, Ahlborg N. Multiplex
- analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot. J
- 553 Immunol Methods 2020;478:112715. https://doi.org/10.1016/j.jim.2019.112715
- 554 26. Ciabattini A, Pastore G, Fiorino F, Polvere J, Lucchesi S, Pettini E, et al. Evidence of
- 555 SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2
- 556 mRNA Vaccine. Front Immunol 2021;12:740708. https://doi.org/10.3389/fimmu.2021.740708
- 557 27. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. Persistence of
- SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months
- after the infection. Med (N Y) 2021;2:281-95 e4. https://doi.org/10.1016/j.medj.2021.02.001
- 560 28. Angsuwatcharakon P, Ratananpinit N, Yoksan S, Saengseesom W, Sriaksorn R,
- Raksahket N, et al. Immunogenicity and safety of two-visit, intradermal pre-exposure rabies
- prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis
- vaccine in children living in rabies and Japanese encephalitis endemic country. Vaccine
- 564 2020;38:5015-20. https://doi.org/10.1016/j.vaccine.2020.05.054

- 565 29. Fritz TM, Trueb RM. [BCG ulcer. Rapid healing with topical INH powder]. Hautarzt
- 566 2002;53:816-8. https://doi.org/10.1007/s00105-002-0367-3
- 567 30. Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and
- intramuscular administration of hepatitis B vaccine in neonates. Indian J Gastroenterol
- 569 2001;20:94-6.
- 570 31. Blanchet K, Mallard G, Moret E, Sun J. Sanctioned countries in the global COVID-19
- vaccination campaign: the forgotten 70. Confl Health 2021;15:69.
- 572 https://doi.org/10.1186/s13031-021-00404-2
- 573 32. Perry M, Akbari A, Cottrell S, Gravenor MB, Roberts R, Lyons RA, et al. Inequalities in
- 574 coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales,
- 575 UK. Vaccine 2021. https://doi.org/10.1016/j.vaccine.2021.09.019
- 576 33. Kupek E. Low COVID-19 vaccination coverage and high COVID-19 mortality rates in
- 577 Brazilian elderly. Rev Bras Epidemiol 2021;24:e210041. https://doi.org/10.1590/1980-
- 578 549720210041
- 579 34. Hannah Ritchie EM, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban
- Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser. Coronavirus
- Pandemic (COVID-19): Our World in Data; 2020 [cited 2021 26 sep 2021]. Available from:
- 582 https://ourworldindata.org/covid-vaccinations. Accessed date 26 September, 2021.
- 583 35. Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused
- review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int
- 585 Immunopharmacol 2021;100:108162. https://doi.org/10.1016/j.intimp.2021.108162
- 586 36. Schweiger M. Intradermal covid-19 vaccination could solve supply problems. BMJ
- 587 2021;374:n1980. https://doi.org/10.1136/bmj.n1980

- 588 37. Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences
- and age. Womens Health (Lond) 2021;17:17455065211022262.
- 590 https://doi.org/10.1177/17455065211022262
- 591 38. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG
- antibody between male and female COVID-19 patients: A possible reason underlying different
- outcome between sex. J Med Virol 2020;92:2050-4. https://doi.org/10.1002/jmv.25989
- 39. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. A simple
- 595 protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 2020;5.
- 596 https://doi.org/10.1172/jci.insight.142362
- 597 40. Meyer B, Reimerink J, Torriani G, Brouwer F, Godeke GJ, Yerly S, et al. Validation and
- 598 clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg
- 599 Microbes Infect 2020;9:2394-403. https://doi.org/10.1080/22221751.2020.1835448
- 600 41. Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C, et al.
- Evaluation of a commercially-available surrogate virus neutralization test for severe acute
- 602 respiratory syndrome coronavirus-2 (SARS-CoV-2). Diagn Microbiol Infect Dis
- 603 2021;99:115294. https://doi.org/10.1016/j.diagmicrobio.2020.115294